Eli Lilly said its oral weight-loss drug Orforglipron cut body weight by 10.5% at 72 weeks in a Phase 3 trial, versus 2.2% with placebo. Tested in 1,600 adults with obesity or type 2 diabetes, the once-daily pill also improved cardiometabolic risk factors. With full data now ready, Lilly will begin global regulatory filings for approval.